Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Heron Therapeutics (HRTX) Receivables - Other (2020 - 2025)

Heron Therapeutics filings provide 6 years of Receivables - Other readings, the most recent being $344000.0 for Q4 2025.

  • On a quarterly basis, Receivables - Other rose 30.8% to $344000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $344000.0, a 30.8% increase, with the full-year FY2025 number at $344000.0, up 30.8% from a year prior.
  • Receivables - Other hit $344000.0 in Q4 2025 for Heron Therapeutics, up from $263000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $6.2 million in Q4 2022 to a low of $103000.0 in Q4 2021.
  • Median Receivables - Other over the past 5 years was $310000.0 (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Receivables - Other: surged 5916.5% in 2022 and later tumbled 95.0% in 2023.
  • Heron Therapeutics' Receivables - Other stood at $103000.0 in 2021, then surged by 5916.5% to $6.2 million in 2022, then tumbled by 95.0% to $310000.0 in 2023, then fell by 15.16% to $263000.0 in 2024, then skyrocketed by 30.8% to $344000.0 in 2025.
  • The last three reported values for Receivables - Other were $344000.0 (Q4 2025), $263000.0 (Q4 2024), and $310000.0 (Q4 2023) per Business Quant data.